Mitigating the impacts of COVID-19: where are the mental health trials?

Gilbody, Simon; Littlewood, Elizabeth; Gascoyne, Samantha; McMillan, Dean; Ekers, David; Chew-Graham, Carolyn A.; Creswell, Cathy; Wright, John

Abstract

COVID-19 prompted rapid mobilisation of health services and medical science in the face of unprecedented challenges. When COVID-19 emerged in 2020, medical science delivered, and delivered quickly. Using large-scale multicentre trials, researchers in partnership with health services established the ability of cheap and scalable interventions (such as corticosteroids) to save lives, and rapidly showed the futility of anecdotally endorsed repurposed drugs (such as hydroxychloroquine). The effectiveness of vaccinations was quickly established in phase 2 and 3 trials, providing the confidence to roll out successful vaccine programmes.

Citation

Gilbody, S., Littlewood, E., Gascoyne, S., McMillan, D., Ekers, D., Chew-Graham, C. A., …Wright, J. (2021). Mitigating the impacts of COVID-19: where are the mental health trials?. The Lancet Psychiatry, 8(8), 647-650. https://doi.org/10.1016/S2215-0366%2821%2900204-2

• Journal Article Type: Article
• Acceptance Date: Jun 1, 2021
• Publication Date: 2021-08
• Deposit Date: Jun 5, 2023
• Journal: LANCET PSYCHIATRY
• Print ISSN: 2215-0366
• Publisher: Elsevier
• Peer Reviewed: Peer Reviewed
• Volume: 8
• Issue: 8
• Pages: 647-650
• DOI: https://doi.org/10.1016/S2215-0366%2821%2900204-2